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RESEARCH ARTICLE Open Access
Recombinant human proteoglycan-4
reduces phagocytosis of urate crystals and
downstream nuclear factor kappa B and
inflammasome activation and production
of cytokines and chemokines in human
and murine macrophages
Marwa Qadri1, Gregory D. Jay2,3, Ling X. Zhang2, Wendy Wong2, Anthony M. Reginato4, Changqi Sun4,
Tannin A. Schmidt5 and Khaled A. Elsaid1*
Abstract
Background: Gout is an inflammatory arthritis caused by monosodium urate monohydrate (MSU) crystals’ joint
deposition. MSU phagocytosis by resident macrophages is a key step in gout pathogenesis. MSU phagocytosis triggers
nuclear factor kappa B (NFκB) activation and production of cytokines and chemokines. Proteoglycan-4 (PRG4) is a
glycoprotein produced by synovial fibroblasts and exerts an anti-inflammatory effect in the joint mediated by its
interaction with cell surface receptor CD44. PRG4 also binds and antagonizes TLR2 and TLR4. The objective of this
study is to evaluate the efficacy of recombinant human PRG4 (rhPRG4) in suppressing MSU-induced inflammation
and mechanical allodynia in vitro and in vivo.
Methods: THP-1 macrophages were incubated with MSU crystals ± rhPRG4 or bovine submaxillary mucin (BSM),
and crystal phagocytosis, cytokines and chemokines expression and production were determined. NFκB p65
subunit nuclear translocation, NLRP3 induction, caspase-1 activation and conversion of proIL-1β to mature IL-1β
were studied. MSU phagocytosis by Prg4+/+ and Prg4−/− peritoneal macrophages was determined in the absence
or presence of rhPRG4, BSM, anti-CD44, anti-TLR2, anti-TLR4 and isotype control antibodies. Rhodamine-labeled
rhPRG4 was incubated with murine macrophages and receptor colocalization studies were performed. Lewis rats
underwent intra-articular injection of MSU crystals followed by intra-articular treatment with PBS or rhPRG4. Weight
bearing and SF myeloperoxidase activities were determined.
(Continued on next page)
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Results: rhPRG4 reduced MSU crystal phagocytosis at 4 h (p < 0.01) and IL-1β, TNF-α, IL-8 and MCP-1 expression and
production at 6 h (p < 0.05). BSM did not alter MSU phagocytosis or IL-1β production in human and murine
macrophages. rhPRG4 treatment reduced NFκB nuclear translocation, NLRP3 expression, caspase-1 activation and
generation of mature IL-1β (p < 0.05). MSU-stimulated IL-1β production was higher in Prg4−/− macrophages compared
to Prg4+/+ macrophages (p < 0.001). rhPRG4, anti-CD44, anti-TLR2 and anti-TLR4 antibody treatments reduced MSU
phagocytosis and IL-1β production in murine macrophages (p < 0.05). rhPRG4 preferentially colocalized with CD44 on
Prg4−/− peritoneal macrophages compared to TLR2 or TLR4 (p < 0.01). rhPRG4 normalized weight bearing and reduced
SF myeloperoxidase activity compared to PBS in vivo.
Conclusion: rhPRG4 inhibits MSU crystal phagocytosis and exhibits an anti-inflammatory and anti-nociceptive activity
in vitro and in vivo. rhPRG4’s anti-inflammatory mechanism may be due to targeting CD44 on macrophages.
Keywords: Gout, Proteoglycan-4, Macrophages, Lubricin, Urate, CD44, TLR2, TLR4
Background
Gout is an inflammatory arthritis characterized by de-
position of monosodium urate monohydrate (MSU)
crystals in synovial joints and periarticular tissues [1, 2].
Gout is characterized by painful episodes of intermittent
acute monoarthritis, most often in peripheral joints such
as the first metatarsophalangeal and knee joints, in the
midst of asymptomatic periods [2, 3]. Tissue MSU
crystal deposits initiate inflammation in resident macro-
phages, mediated in part by pattern recognition recep-
tors of the innate immune system, such as toll-like
receptors (TLR2 and TLR4) [4–8]. Other endogenous
TLR ligands, such as myeloid-related proteins 8 and 14
and long chain fatty acids may play a role in priming
macrophages to the inflammatory effect of MSU crystals
[9, 10]. Priming macrophages stimulates nuclear factor
kappa B (NFκB) nuclear translocation, proIL-1β expres-
sion and induces the expression of NACHT, LRR and
PYD-containing protein 3 (NLRP3) inflammasome com-
ponents: NLRP3 protein, ASC adaptor protein, and
caspase-1 [11–13]. NFκB translocation results in indu-
cing the expression and secretion of proinflammatory
cytokines, e.g. interleukin-1 beta (IL-1β) and tumor ne-
crosis factor alpha (TNF-α) and chemokines, e.g.
interleukin-8 (IL-8) and monocyte chemoattractant
protein-1 (MCP-1) [14–17]. Particulate danger signals
e.g. MSU crystals are thought to cause lysosomal disrup-
tion following their endocytosis by macrophages and
thus trigger inflammasome activation and conversion of
proIL-1β to IL-1β with downstream enhancement of the
inflammatory cascade and inflammatory cell influx to
the affected joint [18–22].
Lubricin/Proteoglycan-4 (PRG4) is a mucinous glyco-
protein secreted by synovial fibroblasts and superficial
zone articular chondrocytes [23–25]. PRG4 is the major
lubricating constituent of synovial fluid (SF) and a bio-
logical role for PRG4 has been described. The recombin-
ant form of PRG4 exhibits an anti-inflammatory role
characterized by its ability to compete with hyaluronan
on binding to the CD44 receptor [26]. The downstream
effect of engaging CD44 by PRG4 is the inhibition of
IL-1β and TNF-α induced NFκB nuclear translocation in
synoviocytes from patients with RA and OA [26, 27].
The autocrine anti-inflammatory role of PRG4 on syn-
ovial fibroblasts was shown to be mediated by its ability
to inhibit the degradation of cytosolic inhibitor kappa B
alpha (IκB-α) in a CD44-dependent manner [27]. Related
to TLRs, recombinant human PRG4 (rhPRG4) binds to,
and regulates agonist-induced activation of TLR2 and
TLR4 [28, 29]. Supplementation of OA and RA synovial
fluid aspirates with the native form of PRG4 inhibited
TLR2 and TLR4 activation by these aspirates [29].
The objective of this study is to evaluate the efficacy of
rhPRG4 related to modulation of MSU crystal uptake by
human and murine macrophages and subsequent cellular
activation and induction of proinflammatory cytokines
and chemokines expression and production. Furthermore,
we studied the ability of rhPRG4 to reduce inflammation
and acute mechanical allodynia in a rat model of intra-
articular MSU challenge. We hypothesized that rhPRG4
inhibits MSU crystal phagocytosis by macrophages
through the inhibition of TLR receptors or CD44, resulting
in a significant reduction in IL-1β, TNF-α, IL-8 and MCP-1
expression and production and an anti-inflammatory and
an anti-nociceptive effect in vivo.
Methods
Differentiation of THP-1 monocytes into macrophages
and studies of time-dependent MSU phagocytosis and
impact of rhPRG4 treatment
THP-1 monocytes (ATCC, USA) were cultured to a dens-
ity of 1.5 × 106 cells/ml in 75 cm2 flask in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS), 10 mM HEPES, 2 mM glutamine,
100 U/L Penicillin and 100μg/ml streptomycin and main-
tained at 37 °C. In sterile 12 well plates (Corning, Sigma
Aldrich, USA), 500,000 cells in 2 ml RPMI 1640 media
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were differentiated into macrophages by incubation with
phorbol 12-myristate-13-acetate (PMA; Sigma Aldrich) to
a final concentration of 5 ng/ml for 48 h [30]. Subse-
quently, media supernatants were removed and wells were
washed with sterile PBS to remove any unattached cells
and new RPMI 1640 media was added.
THP-1 macrophages were treated with endotoxin-free
MSU crystals (100μg/ml; Invivogen, USA) ± bovine sub-
maxillary mucin (BSM; molecular mass > 1000 KDa)
(Sigma Aldrich) (25 μg/ml) or rhPRG4 (molecular mass
is approximately 240 KDa) (100 μg/ml) for 2 and 4 h at
37 °C. rhPRG4 is an endotoxin-free full-length product
produced by CHO-M cells (Lubris, Framingham, MA,
USA) [31]. Subsequently, adherent macrophages were
harvested via trypsinization, pelleted and washed with
PBS. The phagocytosis of MSU crystals was determined
by analyzing change in cell side-scatter using a flow cyt-
ometer (BD FACSVerse, BD Biosciences, USA). Two re-
gions of interest were identified. P1 represents the
THP-1 macrophage population in the absence of MSU
exposure. P2 represents the THP-1 macrophage popula-
tion with increased side-scatter indicative of MSU in-
ternalization. Data are presented as the mean percentage
of cells in the P2 region across different time points and
different treatments, and were derived from four inde-
pendent experiments with duplicate wells per group. All
flow cytometry experiments were performed using the
same acquisition parameters.
Comparative effect of rhPRG4 and BSM on MSU-stimulated
production of proinflammatory cytokines and chemokines
THP-1 macrophages (500,000 cells per well) were treated
with MSU (100μg/ml) ± rhPRG4 (100μg/ml) or BSM
(25μg/ml) for 6 h followed by collection of media superna-
tants. Media concentrations of IL-1β, TNF-α, IL-8 and
MCP-1 were determined using ELISA kits (R&D Systems,
USA). Data represent the mean ± S.D. of four independent
experiments with duplicate wells per group.
Nuclear p65 NFκB translocation and NLRP3 inflammasome
activation following MSU challenge and impact of rhPRG4
treatment
NFκB p65 subunit translocation studies were performed
as previously described [32]. THP-1 macrophages
(600,000 cells per well) were treated with MSU
(100μg/ml) ± rhPRG4 (50 and 100μg/ml) for 1 h followed
by cell harvest and nuclear protein extraction. Nuclear
levels of p65 subunit were determined using a DNA bind-
ing ELISA assay (Abcam) and were normalized to total nu-
clear protein content using the micro BCA assay and
expressed as detectable NFκB p65 levels normalized to un-
treated controls. Data represent the mean ± S.D. of three in-
dependent experiments with duplicate wells per treatment.
THP-1 macrophages (500,000 cells per well) were
treated with MSU (100μg/ml) ± rhPRG4 (100 and
200μg/ml) for 12 h. A positive control treatment (H2O2;
5 mM) was also included in the absence or presence of
rhPRG4 (200μg/ml). Subsequently, cells were washed
twice with ice-cold PBS and lysed on ice in RIPA buffer
for 30 min and centrifuged for 5 min (16,000 g at 4 °C).
The supernatant was collected and total cellular protein
was quantified using BCA protein assay kit (Thermo-
Fisher Scientific). Equal amounts of protein (40–50 μg)
were loaded and separated by a 12% SDS-PAGE gel.
Following blotting, membranes were blocked using 5%
non-fat dry milk and probed with primary antibodies
overnight at 4 °C. These antibodies included proIL-1β
(D3U3E; Cell Signal Technology, USA), cleaved IL-1β
(D3A3Z; Cell Signal Technology), NLRP3 (D2P5E; Cell
Signal Technology), and capase-1 (MAB6216; R&D
Systems). Target proteins were detected using IRDye
secondary goat anti-mouse or goat anti-rabbit antibodies
(LI-COR Biosciences, USA) and visualized with LI-COR
Odyssey Blot Imager (LI-COR Biosciences).
Dose-dependent effect of rhPRG4 treatment on MSU-induced
proinflammatory cytokines and chemokines gene expression
and production in THP-1 macrophages
THP-1 macrophages (500,000 cells per well) were treated
with MSU (100μg/ml) ± rhPRG4 (25, 50, 100 and 200μg/
ml) for 6 h. Total RNA was extracted using TRIzol reagent
(Thermo Fisher Scientific), and RNA concentrations were
determined with a NanoDrop ND-2000 spectrophotom-
eter (NanoDrop Technologies, USA). cDNA was synthe-
sized using Transcriptor First Strand cDNA Synthesis Kit
(Roche, USA). Quantitative PCR (qPCR) was performed
on Applied Biosystems Step One Plus Real-Time PCR
System (Thermo Fisher Scientific) using TaqMan Fast Ad-
vanced Master Mix (Life Technologies, USA). Genes of
interest included IL-1β (Hs00174097_m1, ThermoFisher
Scientific), TNF-α (Hs01113624_g1, ThermoFisher
Scientific), IL-8 (Hs00174103_m1, ThermoFisher Scien-
tific) and MCP-1 (Hs00234140_m1, ThermoFisher Scien-
tific). The cycle threshold (Ct) value of target genes was
normalized to the Ct value of GAPDH (Hs02758991_g1;
Thermo Fisher Scientific) in the same sample, and the
relative expression was calculated using the 2-ΔΔCt method
[33]. Data are presented as fold target gene expression
compared to untreated control. Data represent mean ± S.D.
of three independent experiments with duplicate wells per
treatment.
THP-1 macrophages (500,000 cells per well) were
treated with MSU (100μg/ml) ± rhPRG4 (100 and
200μg/ml) for 24 H. media concentrations of IL-1β,
TNF-α, IL-8 and MCP-1 were determined using com-
mercially available ELISA kits (R&D Systems). Data
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represent the mean ± S.D. of three independent experi-
ments with duplicate wells per group.
Isolation of peritoneal macrophages from Prg4+/+ and Prg4−/−
mice, phagocytosis of MSU crystals by murine macrophages
and downstream production of IL-1β and comparative
efficacy of rhPRG4, anti-CD44, anti-TLR2 and anti-TLR4
antibody treatments
The phenotype of the Prg4−/− mouse has been previously
reported [34], and is characterized by cartilage degener-
ation and a hyperplastic synovium contributing to joint
failure [34]. The Prg4−/− and Prg4+/+ mouse colonies are
maintained at Rhode Island Hospital. Prg4−/− mouse is
also commercially available (stock #025737; The Jackson
Laboratory, Maine, USA). Isolation of murine peritoneal
macrophages was performed as previously described
[35] following IACUC approval at Rhode Island
Hospital. A total of 20 Prg4+/+ and 20 Prg4−/− mice were
euthanized. Subsequently, the abdomen of each mouse
was soaked with 70% alcohol and a small incision was
made along the midline with scissors. Using blunt dis-
section, the abdominal skin was retracted to expose the
intact peritoneal wall. A 27 G needle attached to a 10 ml
syringe filled with sterile cold PBS was inserted through
the peritoneal wall at the midline and injected into each
mouse, aspirated slowly from the peritoneum, and peri-
toneal macrophages cells were collected. Subsequently,
cells were centrifuged at 10,000 rpm and 4 °C for
10 min. Pelleted cells were re-suspended in RPMI 1640
medium supplemented with 10% FBS and 1% Penicillin/
Streptomycin.
Murine peritoneal macrophages were plated onto
sterile chamber slides (ThermoFisher Scientific) at a
concentration of 1.3 × 106 cells/well. Cells were allowed
to adhere by incubation at 37 °C for 24 h. Following in-
cubation, media and non-adherent cells were removed
and fresh media was added. Treatments included
untreated control cells, MSU (100μg/ml) ± rhPRG4
(100μg/ml), BSM (25μg/ml), anti-CD44 (Abcam; 2μg/ml),
anti-TLR2 (Abcam; 2μg/ml), anti-TLR4 (Abcam; 2μg/ml)
and isotype control (IC; 2μg/ml) (Abcam) antibodies.
Incubations were performed for 4 and 24 h. Subse-
quently, slides were washed once with PBS and then
fixed with 4% formalin for 15 min. Slides were subse-
quently washed with PBS and cells were permeabilized
with 0.1% Triton X100 for 10 min. After washing with
PBS for three times, slides were mounted with DAPI
mounting medium (Vector Lab, USA) and viewed
under a microscope (Nikon E800). The number of
intracellular MSU crystals in 8 areas for a total of 900
cells was determined and the total number of MSU
crystals was reported. Data represent the mean ± S.D. of
four to five independent experiments. Media
supernatants were assayed for IL-1β concentrations
using a murine ELISA kit (R&D Systems).
Colocalization of rhPRG4 and CD44, TLR2 and TLR4
receptors in Prg4−/− peritoneal macrophages
Isolation and culture of Prg4−/− peritoneal macrophages
was performed as described above. Rhodamine labeling of
rhPRG4 was performed using the Pierce NHS-Rhodamine
Antibody Labeling Kit (Thermo Fisher Scientific).
Rhodamine labeled rhPRG4 (25μg/ml) was incubated with
Prg4−/− macrophages for 2 h. Subsequently, media was re-
moved and cells were washed with PBS and fixed using
4% formalin for 15 min at room temperature. Cells were
then permeabilized with 0.2% Triton X-100 for 10 min
and subsequently blocked with 2% BSA for 30 min. Cells
were incubated with CD44 antibody, TLR2 antibody,
TLR4 antibody or an isotype control (Abcam) (1:200
dilution) overnight at 4 °C. Cells were then washed with
PBS and incubated with Alexa Fluor 488 goat anti-rabbit
IgG (Thermo Fisher Scientific) at 1:200 dilution for 1 h at
room temperature. After washing with PBS for three
times, slides were mounted with DAPI mounting medium
(Vector Lab). Confocal images were acquired with a
Nikon C1si confocal microscope (Nikon Inc., USA) using
diode lasers 402, 488 and 561. Serial optical sections were
obtained sequentially with EZ-C1 computer software’s
frame lambda setting. Z series sections were collected at
0.2 μm with a 60× Plan Apo, 1.4 numerical aperture lens.
Six to seven fields were collected per sample for a total
minimum number of 100 cells. All colocalization analyses
were performed on deconvolved, 3D acquisitions
(Elements version 3.2, Nikon Inc.). In each Z stack, cells
were outlined and analyzed with Nikon’s colocalization
macro. Pearson’s Correlation Coefficient was used to de-
termine colocalization. A minimum threshold of Pearson’s
Coefficient > 0.5 was used to indicate positive colocaliza-
tion. Data is presented as percent of cells positive for
rhPRG4 and receptor colocalization and is expressed as
mean ± standard deviation of 3 experiments.
Crystal-induced inflammation and mechanical allodynia in
the rat and the impact of rhPRG4 treatment
Male Lewis rats (n = 40; 10 weeks old) (Charles River,
USA) were randomly assigned to three experimental
groups; MSU only, MSU + PBS or MSU + rhPRG4. All an-
imals received an intra-articular injection of pyrogen-free
MSU suspension (50 μl; 5 mg/ml). Intra-articular injec-
tions were performed under gas anesthesia (5% isoflur-
ane). Intra-articular injections were performed in the right
knee joints. The skin around the right knee joint was
shaved and the injection site was cleansed using a topical
iodine-based antiseptic and 70% isopropranolol. At 1 h
following MSU injection, animals received PBS (50 μl),
rhPRG4 (50 μl; 1 mg/ml) or remained untreated. We have
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also included 4 animals that received intra-articular
PBS (50 μl).
Static weight bearing of the hind limbs of animals at
baseline and at 3 and 6 h post-MSU injection (n = 12 in
the MSU alone group and n = 14 in PBS and
rhPRG4-treated animals) and at 24 h post-MSU injection
(n = 5 in MSU alone and n = 7 in PBS and rhPRG4-treated
animals) was measured using an Incapacitance Meter
(Harvard Apparatus, USA). Data are presented as differen-
tial weight bearing between the hind right limb and
the hind left limb. Animals were euthanized either at
6 h (n = 7 in each group) or at 24 h (n = 5 in MSU alone
and n = 7 in PBS and rhPRG4-treated animals) following
MSU challenge. Lavaging of the right knee joint was per-
formed by injecting 100 μl of normal saline followed by
joint flexion and extension and aspirating ~ 20–30 μl of
SF lavage. Animal sera were also collected. Myeloperoxi-
dase (MPO) activity in SF lavage samples was measured
using a commercially available kit (Abcam). SF lavage and
serum urea concentrations of each animal were deter-
mined using a urea assay kit (Abcam) and the fold dilution
in SF lavage was calculated [36, 37]. Data are expressed as
MPO activity (μU) adjusted to fold urea dilution. SF lava-
ging was performed for 2 untreated control animals and 4
PBS-injected animals and SF lavage MPO activity was de-
termined as described above. All animal studies were ap-
proved by the IACUC committee at MCPHS University.
Statistical analyses
Statistical analyses of gene expression data were per-
formed using ΔCt values (Ct target gene-Ct GAPDH) for
each gene of interest in each experimental group and
data were graphically presented as fold expression rela-
tive to untreated controls using the 2-ΔΔCt method. Con-
tinuous variables were initially evaluated whether they
satisfy the requirements for parametric statistical tests.
Statistical significance comparing two groups or multiple
groups with parametric data was assessed by Student’s t
test or ANOVA followed by post-hoc multiple compari-
sons using Tukey’s post-hoc test. Statistical significance
comparing two groups or multiple groups with nonpara-
metric data was assessed by Rank Sum test or ANOVA
on the ranks. Analysis of MSU phagocytosis by THP-1
macrophages following 2 and 4-h incubations and im-
pact of rhPRG4 or BSM treatments was performed using
2-way ANOVA. A p value of < 0.05 was considered sta-
tistically significant.
Results
rhPRG4 treatment reduced MSU crystal phagocytosis by
THP-1 macrophages
Representative MSU phagocytosis flow cytometry scat-
terplots are presented in Fig. 1. Qualitatively, THP-1
macrophages internalized MSU crystals at 2 and 4 h
with more cells appearing in the P2 region of interest at
4 h compared to 2 h (Fig. 1b and e). rhPRG4 treatment
appeared to reduce the number of THP-1 macrophages
in the P2 region, especially following incubation for 4 h
(Fig. 1f ). BSM treatment as a negative control mucin did
not appear to modify MSU phagocytosis by THP-1 mac-
rophages (Fig. 1d and g). rhPRG4 or BSM alone did not
appear to alter the side scattering of THP-1 macro-
phages (Fig. 1h and i). The percentage of positive cells in
the 2-h MSU group was higher than the percentage of
positive cells in the corresponding control group
(p = 0.022) (Fig. 1j). Similarly, the percentage of positive
cells in the 4-h MSU group was higher than the percent-
age of positive cells in the corresponding control
group (p = 0.0002). MSU phagocytosis by THP-1 macro-
phages at 4 h was higher than MSU phagocytosis by
THP-1 macrophages at 2 h (p = 0.003). rhPRG4 or BSM
treatments did not alter MSU phagocytosis by THP-1
macrophages at 2 h (p = 0.461; p = 0.999) (Fig. 1k). In con-
trast, rhPRG4 significantly reduced MSU phagocytosis by
THP-1 macrophages at 4 h (p < 0.001). BSM treatment
did not alter MSU phagocytosis by THP-1 macrophages
at 4 h (p = 0.981), and the percentage of positive cells in
the MSU + BSM group was higher than the percentage of
positive cells in the MSU + rhPRG4 group (p = 0.001).
There was no significant difference in percentage of posi-
tive cells between rhPRG4-treated or BSM-treated macro-
phages and untreated controls at 2 or 4 h (p > 0.999 for all
comparisons).
rhPRG4 treatment reduced MSU stimulated cytokine and
chemokine gene expression and production mediated by
a reduction in NLRP3 inflammasome activation and NFκB
nuclear translocation
Incubation of THP-1 macrophages with MSU crystals
resulted in a significant increase in IL-1β, TNF-α,
IL-8 and MCP-1 production by the macrophages at
6 h (p < 0.001; p = 0.004; p < 0.001; p < 0.001) (Fig. 2a
through d). rhPRG4 and BSM treatments did not signifi-
cantly alter basal cytokine and chemokine production by
THP-1 macrophages (p > 0.05 for all comparisons).
rhPRG4 treatment significantly reduced MSU-induced
IL-1β (p < 0.001), TNF-α (p = 0.003), IL-8 (p < 0.001) and
MCP-1 (p = 0.003) production by THP-1 macrophages at
6 h. In contrast, BSM treatment did not significantly alter
MSU-induced cytokines and chemokines production
(p = 0.305; p = 0.365; p = 0.964; p = 0.998). Media concen-
trations of IL-1β, IL-8 and MCP-1 were significantly
lower in the MSU + rhPRG4 group compared to the
MSU + BSM group (p < 0.001; p = 0.002, p = 0.003).
MSU crystals enhanced nuclear NFκB nuclear trans-
location in THP-1 macrophages compared to untreated
control cells (Fig. 2e) (p < 0.001). rhPRG4 treatments at
50 and 100 μg/ml significantly reduced MSU stimulated
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Fig. 1 Time and treatment-dependent phagocytosis of monosodium urate monohydrate (MSU) crystals by differentiated human THP-1 macrophages
using flow cytometry and impact of recombinant human proteoglycan-4 (rhPRG4) or bovine submaxillary mucin (BSM) treatments following 2 and 4-h
incubations. Quantitative determination of MSU phagocytosis was performed using the percentage of cells in the P2 region of interest. Data represent
the mean ± S.D. of four independent experiments. *p < 0.001; **p < 0.01; ***p < 0.05. a Representative flow cytometry scatterplot of untreated human
THP-1 macrophages. b Representative flow cytometry scatterplot of MSU-treated THP-1 macrophages for 2 h. c Representative flow cytometry
scatterplot of MSU + rhPRG4 (100 μg/ml)-treated THP-1 macrophages for 2 h. d Representative flow cytometry scatterplot of MSU + BSM (25 μg/ml)-
treated THP-1 macrophages for 2 h. e Representative flow cytometry scatterplot of MSU-treated THP-1 macrophages for 4 h. f Representative flow
cytometry scatterplot of MSU+ rhPRG4 (100 μg/ml)-treated THP-1 macrophages for 4 h. g Representative flow cytometry scatterplot of MSU+ BSM
(25 μg/ml)-treated THP-1 macrophages for 4 h. h Representative flow cytometry scatterplot of rhPRG4 (100 μg/ml)-treated THP-1 macrophages for 4 h. i
Representative flow cytometry scatterplot of BSM (25 μg/ml)-treated THP-1 macrophages for 4 h. j Phagocytosis of MSU crystals by THP-1
macrophages was higher in following 4-h incubation compared to 2-h incubation. k rhPRG4 treatment reduced MSU phagocytosis by THP-1
macrophages at 4 h compared to BSM
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Fig. 2 (See legend on next page.)
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NFκB nuclear translocation in THP-1 macrophages
(p = 0.039; p = 0.008).
MSU crystals induced IL-1β expression compared to un-
treated macrophages (p < 0.001) (Fig. 2f). rhPRG4 (100 and
200μg/ml) treatments reduced IL-1β expression in THP-1
macrophages (p = 0.002; p = 0.001). Likewise, MSU crystals
significantly induced TNF-α expression compared to un-
treated macrophages (p < 0.001) (Fig. 2g). rhPRG4 (25, 50,
100 and 200μg/ml) treatments reduced TNF-α expression
compared to MSU alone group (p = 0.009; p < 0.001;
p < 0.001; p < 0.001). MSU crystals significantly induced
chemokines IL-8 and MCP-1 expression compared to
untreated macrophages (p < 0.001) (Fig. 2h and i).
rhPRG4 (50, 100 and 200μg/ml) treatments reduced IL-8
expression compared to MSU alone group (p = 0.031;
p = 0.015; p = 0.009). Similarly, rhPRG4 (50, 100 and
200μg/ml) treatments reduced MCP-1 expression compared
to MSU alone group (p= 0.012; p= 0.002; p= 0.001).
At 24 h, treatment with MSU crystals resulted in ele-
vated IL-1β media concentrations compared to controls
(p < 0.001) (Fig. 2j). rhPRG4 (100 and 200μg/ml) treat-
ment reduced MSU-induced IL-1β production by macro-
phages (p = 0.003; p = 0.001). MSU crystals significantly
increased TNF-α production by THP-1 macrophages
(p = 0.004) (Fig. 2k). rhPRG4 (100 and 200μg/ml) treatments
significantly reduced MSU-induced TNF-α production by
macrophages (p = 0.003; p= 0.009). MSU crystals signifi-
cantly induced IL-8 and MCP-1 production by macrophages
(p < 0.001) (Fig. 2l and m). rhPRG4 (200μg/ml) treatment
significantly reduced MSU-stimulated IL-8 and MCP-1
production by macrophages (p = 0.004; p < 0.001). rhPRG4
(100 and 200μg/ml) alone did not alter the basal levels of
cytokines and chemokines (p > 0.05 for all comparisons).
MSU activated the NLRP3 inflammasome as evi-
denced by increased cytosolic NLRP3 protein levels in
THP-1 macrophages, activated procaspase-1 and in-
creased conversion of proIL-1β to active IL-1β (Fig. 3a).
rhPRG4 (100 and 200μg/ml) treatments reduced cyto-
solic NLRP3 protein levels compared to MSU treatment
alone (p < 0.05; p < 0.001) (Fig. 3b). Similarly, rhPRG4
(100 and 200μg/ml) treatments reduced procaspase-1 acti-
vation (p < 0.001 for both comparisons; Fig. 3c) and the
200μg/ml treatment level had a lower level of intracellular
mature IL-1β (p < 0.05; Fig. 3d). rhPRG4 treatment at
200 μg/ml did not alter H2O2 induced NLRP3 induction,
caspase-1 activation or mature IL-1β generation (p > 0.05).
Prg4−/− peritoneal macrophages demonstrated enhanced
MSU crystal intracellular localization at 24 h and IL-1β
production compared to Prg4+/+ peritoneal macrophages
Phagocytosis of MSU crystals by Prg4−/− and Prg4+/+ peri-
toneal macrophages are shown in Figs. 3 and 4. MSU crys-
tals appeared to have been internalized by macrophages
from both genotypes as early as 4 h and continued to be
detected up to 24 h. At 4 h, there was no significant differ-
ence in intracellular MSU crystal count between Prg4−/−
and prg4+/+ macrophages (p = 0.739) (Fig. 4b). In contrast,
we have observed a significantly higher number of MSU
crystals in Prg4−/− macrophages compared to Prg4+/+
macrophages (p = 0.019) at 24 h (Fig. 5b). Prg4−/− periton-
eal macrophages secreted significantly higher quantities of
IL-1β compared to Prg4+/+ peritoneal macrophages at 4 h
(p < 0.001) (Fig. 4c) and 24 h (p < 0.001) (Fig. 5c).
Neutralization of CD44, TLR2 and TLR4 receptors reduced
MSU crystal phagocytosis and downstream IL-1β production
in primary murine peritoneal macrophages similar to rhPRG4
Representative images of DAPI-stained Prg4−/− and
Prg4+/+ peritoneal macrophages showing the impact of
rhPRG4, BSM, anti-CD44, anti-TLR2, anti-TLR4 and IC
(See figure on previous page.)
Fig. 2 Impact of recombinant human proteoglycan-4 (rhPRG4) treatment on monosodium urate monohydrate (MSU) crystal-induced expression
and production of proinflammatory cytokines and chemokines and nuclear factor kappa b (NFκB) p65 subunit nuclear translocation in THP-1
macrophages. Cytokines included interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). Chemokines included interleukin-8 (IL-8) and
monocyte chemoattractant protein-1 (MCP-1). Gene expression data are presented as fold induction of proinflammatory cytokines and chemokines
gene expression compared to control untreated THP-1 macrophages. THP-1 macrophages were treated with MSU crystals (100μg/ml) ± rhPRG4
(100μg/ml) or bovine submaxillary mucin (BSM; 25μg/ml) for 6 h (a through d). NFκB p65 subunit nuclear translocation in THP-1 macrophages was
performed at 1 h following MSU challenge (100μg/ml). Gene expression studies were performed at 6 h (f through i) and cytokine and chemokine
media concentrations were determined at 24 h (j through m). Data represent the mean ± S.D. of three to four independent experiments with
duplicate wells per group. *p < 0.001; **p < 0.01; ***p < 0.05. a rhPRG4 treatment reduced MSU-stimulated production of IL-1β by THP-1 macrophages.
b rhPRG4 treatment reduced MSU-stimulated production of TNF-α by THP-1 macrophages. c rhPRG4 treatment reduced MSU-stimulated production
of IL-8 by THP-1 macrophages. d rhPRG4 treatment reduced MSU-stimulated production of MCP-1 by THP-1 macrophages. e rhPRG4 treatment
reduced MSU-stimulated NFκB p65 subunit nuclear translocation in THP-1 macrophages. f rhPRG4 (100 and 200μg/ml) treatment reduced IL-1β gene
expression in MSU-stimulated THP-1 macrophages. g rhPRG4 (25, 50, 100 and 200μg/ml) treatment reduced TNF-α gene expression in MSU-stimulated
THP-1 macrophages. h rhPRG4 (50, 100 and 200μg/ml) treatment reduced IL-8 gene expression in MSU-stimulated THP-1 macrophages. i rhPRG4
(50, 100 and 200μg/ml) treatment reduced MCP-1 gene expression in MSU-stimulated THP-1 macrophages. j rhPRG4 (100 and 200μg/ml) treatment
reduced IL-1β production by MSU-stimulated THP-1 macrophages. k rhPRG4 (100 and 200μg/ml) treatment reduced TNF-α production by MSU-stimulated
THP-1 macrophages. l rhPRG4 (200μg/ml) treatment reduced IL-8 production by MSU-stimulated THP-1 macrophages.m rhPRG4 (200μg/ml) treatment
reduced MCP-1 production by MSU-stimulated THP-1 macrophages
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antibodies treatments at 4 and 24 h are shown in Figs. 4a
and 5a. rhPRG4 significantly reduced MSU crystal
uptake by peritoneal macrophages from both genotypes at
4 and 24 h (p < 0.001 for all comparisons) (Fig. 4b and 5b).
In contrast, BSM treatment had no significant effect on
MSU phagocytosis (p > 0.05 for all comparisons).
Neutralization of CD44, TLR2 and TLR4 receptors sig-
nificantly reduced MSU phagocytosis in Prg4−/− and
Prg4+/+ peritoneal macrophages at 4 and 24 h incuba-
tions (p < 0.01 for all comparisons). Treatment with IC
did not alter MSU phagocytosis by Prg4−/− and Prg4+/+
macrophages at 4 h and crystal phagocytosis by Prg4+/+
macrophages at 24 h (p > 0.05 for all comparisons). We
observed a non-specific effect of antibody treatment on
MSU uptake by Prg4−/− peritoneal macrophages at
24 h. MSU phagocytosis in the MSU + IC group was
significantly lower than MSU phagocytosis in MSU
alone group (p < 0.05). The percent positive cells with
increased side scattering due to MSU phagocytosis was
significantly reduced with rhPRG4 treatment at 6 h
(p < 0.001; Fig. 4e).
Media concentrations of IL-1β were significantly lower
with rhPRG4, anti-CD44, anti-TLR2 and anti-TLR4
treatments at 4 and 24 h utilizing Prg4−/− peritoneal
macrophages (p < 0.0.5 for all comparisons) (Fig. 4c and
5c). Likewise, media concentrations of IL-β were signifi-
cantly lower with rhPRG4, anti-CD44, anti-TLR2 and
anti-TLR4 treatments at 24 h utilizing Prg4+/+ macro-
phages. Only rhPRG4 and anti-CD44 treatments signifi-
cantly reduced IL-1β production in Prg4+/+ macrophages
at 4 h (p < 0.01). Neither anti-TLR2 nor anti-TLR4
significantly reduced IL-1β production in Prg4+/+ macro-
phages at 4 h (p > 0.05). We did not detect a non-specific
effect by BSM or IC treatments utilizing Prg4+/+ peritoneal
macrophages at 4 and 24 h or at 4 h utilizing Prg4−/− mac-
rophages. We observed a non-specific effect of antibody
treatment on MSU-stimulated IL-1β production in Prg4−/−
peritoneal macrophages at 24 h. IL-1β concentrations in
Fig. 3 Impact of recombinant human proteoglycan-4 (rhPRG4) treatment on monosodium urate monohydrate (MSU) crystal-induced NLRP3
inflammasome activation in THP-1 macrophages. THP-1 macrophages were treated with 100μg/ml MSU in the absence or presence of rhPRG4
(100 and 200μg/ml) for 12 h. H2O2 (5 mM) was used as a positive control. Data represent the mean ± S.D. of three independent experiments.
*p < 0.001; **p < 0.01; ***p < 0.05; n.s.: non-significant. a A representative Western Blot of inflammasome components NLRP3 and procaspase-1,
pro-IL-1β, active caspase-1 (p10) and active IL-1β (p17). rhPRG4 treatment reduced NLRP3 induction, procaspase-1 activation and conversion of
pro IL-1β to active IL-1β (p17) but did not modify H2O2 induced inflammasome activation. b rhPRG4 (100 and 200μg/ml) treatment reduced NLRP3
protein in MSU-stimulated THP-1 macrophages. c rhPRG4 (100 and 200μg/ml) treatment reduced caspase-1 (p10) protein in MSU-stimulated THP-1
macrophages. d rhPRG4 (200μg/ml) treatment reduced IL-1β (p17) protein in MSU-stimulated THP-1 macrophages
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the MSU+ IC group were significantly lower than
corresponding concentrations in the MSU alone group
(p < 0.05). Antibody-mediated neutralization of the CD44,
TLR2 and TLR4 receptors yielded similar efficacy in redu-
cing MSU crystal phagocytosis and IL-1β production simi-
lar to rhPRG4 treatment.
rhPRG4 preferentially colocalized with CD44 receptor on
Prg4−/− peritoneal macrophages
Representative colocalization images of rhPRG4 and
CD44, TLR2 and TLR4 receptors are shown in Fig. 6b, c
and d, respectively. We have qualitatively observed more
colocalization of rhPRG4 with CD44 compared to TLR2
or TLR4 receptors. Furthermore, internalization of
rhPRG4 with CD44 was also observed. The mean per-
centage of peritoneal macrophages that were positive for
rhPRG4 and CD44 colocalization was 55.56% compared
to 17.21% for rhPRG4 and TLR2 colocalization and
40.78% for rhPRG4 and TLR4 colocalization. rhPRG4
and CD44 colocalization was significantly higher than
rhPRG4 and TLR2 colocalization (p < 0.001) and rhPRG4
and TLR4 colocalization (p < 0.01) (Fig. 6e). Additionally,
rhPRG4 and TLR4 colocalization was significantly higher
than rhPRG4 and TLR2 colocalization (p < 0.01).
rhPRG4 treatment normalized weight bearing and reduced
SF myeloperoxidase activity
Differential weight bearing in the MSU alone group at 3
and 6 h was significantly lower than the differential
weight bearing at baseline (p = 0.007; p < 0.001) (Fig. 7a).
Additionally, the differential weight bearing in the MSU
alone group at 6 h was significantly lower than corre-
sponding values at 3 h (p < 0.001). At 3 h, there was no
significant change in differential weight bearing in PBS
or rhPRG4-treated animals vs. MSU alone (p = 0.968;
p = 0.421). At 6 h, rhPRG4 treatment normalized weight
Fig. 4 Comparative efficacy of recombinant human proteoglycan-4 (rhPRG4; 100μg/ml), bovine submaxillary mucin (BSM; 25μg/ml), anti-CD44,
anti-toll-like receptor 2 (TLR2), anti-toll-like receptor 4 (TLR4) and isotype control (IC) antibodies (2μg/ml for all antibodies) treatments on phagocytosis
of monosodium urate monohydrate (MSU; 100μg/ml) crystals by primary peritoneal murine macrophages from Prg4+/+ and Prg4−/− mice following a
4-h incubation and production of interleukin-1 beta (IL-1β). Data represent the mean ± S.D. of four independent experiments. *p < 0.001; **p < 0.01;
***p < 0.05. Scale = 50 μm. a Representative images of DAPI-stained peritoneal macrophages from Prg4+/+ and Prg4−/− mice with all treatments. Arrows
point to MSU crystals localized intracellularly. rhPRG4, anti-CD44, ani-TLR2 and anti-TLR4 treatments reduced MSU phagocytosis by Prg4+/+ and Prg4−/−
peritoneal macrophages. b Intracellular count of MSU crystals in Prg4+/+ and Prg4−/− peritoneal macrophages. A specific effect for rhPRG4, anti-CD44,
anti-TLR2 and anti-TLR4 treatments was observed. c rhPRG4 and anti-CD44 antibody treatments reduced IL-1β production by Prg4+/+ and Prg4−/−
peritoneal macrophages. rhPRG4, anti-CD44, anti-TLR2 and anti-TLR4 treatments reduced IL-1β production by Prg4−/− peritoneal macrophages. d
Representative flow cytometry of MSU-treated macrophages in the absence or presence of rhPRG4 (100μg/ml) for 6 h. e rhPRG4 treatment reduced
MSU phagocytosis at 6 h
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bearing as differential weight bearing values in rhPRG4-
treated animals were significantly higher than correspond-
ing values in MSU alone or MSU+ PBS groups (p < 0.001
for both comparisons). There was no observed effect for
PBS treatment compared to MSU alone (p = 0.2770). At
24 h, weight bearing in all experimental groups returned to
baseline. There was no detectable SF lavage MPO activity
in untreated control and PBS-injected animals (Fig. 7b). At
6 h, mean SF lavage MPO activity in rhPRG4 treated ani-
mals was significantly lower than corresponding value in
PBS-treated and MSU alone animals (p = 0.018; p = 0.007).
There was no significant difference in mean SF lavage
MPO activity between MSU alone and MSU+ PBS groups
at 6 h (p = 0.894). At 24 h, there were no significant differ-
ences among the different experimental groups (p > 0.05
for all comparisons).
Discussion
In this work, we studied the activation of macrophages
from human and murine origins by MSU crystals and
evaluated the consequence of rhPRG4 treatment on
MSU induced inflammation. MSU crystals were phago-
cytosed by macrophages in a time-dependent manner
resulting in an increase in NFκB p65 subunit nuclear
translocation, induction of NLRP3 protein, activation of
procaspase-1 enzyme and conversion of proIL-1β to ma-
ture IL-1β. The downstream effects included the induc-
tion of the expression and production of IL-1β, TNF-α,
IL-8 and MCP-1 over a 24-h period. Concentrations of
these cytokines and chemokines produced by macro-
phages subsequent to MSU crystal stimulation were de-
tectable as early as 4 h in murine macrophages and 6 h
in human macrophages and remained elevated over a
24-h period. The induction of cytokines and chemokines
gene expression and production secondary to MSU
stimulation was most pronounced for IL-1β and IL-8.
This observation is in agreement with previous reports
demonstrating enhanced IL-1β and IL-8 expression and
production by macrophages in vitro [22, 38]. PRG4’s
protein core is 1404 amino acid long with N and C
Fig. 5 Comparative efficacy of recombinant human proteoglycan-4 (rhPRG4; 100μg/ml), bovine submaxillary mucin (BSM; 25μg/ml), anti-CD44,
anti-toll-like receptor 2 (TLR2), anti-toll-like receptor 4 (TLR4) and isotype control (IC) antibodies (2μg/ml for all antibodies) treatments on phagocytosis
of monosodium urate monohydrate (MSU; 100μg/ml) crystals by primary peritoneal murine macrophages from Prg4+/+ and Prg4−/− mice following a
24-h incubation and production of interleukin-1 beta (IL-1β). Data represent the mean ± S.D. of five independent experiments. *p < 0.001; **p < 0.01;
***p < 0.05. Scale = 50 μm. a Representative images of DAPI-stained peritoneal macrophages from Prg4+/+ and Prg4−/− mice with all treatments. Arrows
point to MSU crystals localized intracellularly. rhPRG4, anti-CD44, ani-TLR2 and anti-TLR4 treatments reduced MSU phagocytosis by Prg4+/+ and Prg4−/−
peritoneal macrophages. b Intracellular count of MSU crystals in Prg4+/+ and Prg4−/− peritoneal macrophages. A specific effect for rhPRG4, anti-CD44,
anti-TLR2 and anti-TLR4 treatments was observed. c rhPRG4, anti-CD44, anti-TLR2 and anti-TLR4 treatments reduced IL-1β production by Prg4+/+ and
Prg4−/− peritoneal macrophages
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termini and a central mucin domain that is heavily glyco-
sylated via O-linked β(1–3) Gal-GalNAc oligosaccharides,
and is configured to form a nanofilm that exerts repulsive
forces, and provides the basis for its anti-adhesive and lu-
bricating properties [39]. We studied the efficacy of
rhPRG4 against submaxillary mucin to evaluate the extent
of any non-specific biophysical effect that may have re-
sulted from the mucinous nature of rhPRG4 [40].
Contrary to rhPRG4, submaxillary mucin showed no ap-
preciable effect on MSU phagocytosis or MSU-induced
inflammation in both murine and human macro-
phages. rhPRG4 demonstrated a time-dependent and
concentration-dependent inhibition of MSU crystal
phagocytosis and NFκB nuclear activation as well as a re-
duction in NLRP3 inflammasome activation. rhPRG4
dose-dependently reduced MSU-induced gene expression
and production of IL-1β, TNF-α, IL-8 and MCP-1. TNF-α
and IL-8 gene expression and production were most sus-
ceptible to the inhibitory effect of rhPRG4. Overall,
rhPRG4 exhibited an anti-inflammatory activity at
physiologically relevant concentrations that have been
previously reported in SF aspirates from normal subjects
and from patients with OA [41]. The inhibitory effect of
rhPRG4 on inflammasome activation was specific for uric
acid crystals as rhPRG4 failed to inhibit inflammasome ac-
tivation due to the generation of reactive oxygen species.
PRG4 plays a homeostatic role in the articular joint
with an established role in regulating synovial over-
growth and preserving cartilage integrity [42, 43]. Find-
ings in joints from Prg4−/− mice include synovial
hyperplasia, cartilage surface fibrillations and chondro-
cyte apoptosis [34, 43–45]. These pathological changes
are mostly irreversible even with restoration of PRG4 ex-
pression [45]. Interestingly, synoviocytes isolated from
knee synovial tissues of Prg4−/− mice exhibit a proin-
flammatory phenotype characterized by upregulation of
CD44 receptor and enhanced basal and cytokine in-
duced proliferation compared to synoviocytes isolated
from wild type animals [26]. We have isolated peritoneal
macrophages from Prg4−/− and Prg4+/+ animals and
Fig. 6 Colocalization of rhodamine-labeled recombinant human proteoglycan-4 (rhPRG4) (red) and isotype control (IC), CD44 (probed using anti-CD44),
toll-like receptor 2 (TLR2) (probed using anti-TLR2) or toll-like receptor 4 (TLR4) (probed using anti-TLR4) in peritoneal Prg4−/− murine macrophages. Cells
were incubated with rhodamine-rhPRG4 for 2 h followed by cell fixation and permeabilization. Following receptor probing, cells were incubated with
Alexa Fluor 488 conjugated secondary antibody (green) and counterstained with DAPI (blue). Arrows point to co-localization of rhPRG4 with respective
receptors. Quantitative colocalization analysis was performed using Pearson’s Correlation Coefficient and a cutoff of r2 > 0.5 was used to indicate positive
colocalization. The percentage of cells with positive colocalization was determined and at least 100 cells were examined for each treatment condition.
Data represent the mean ± S.D. of three independent experiments. Median colocalization images are presented. *p < 0.001; **p < 0.01;
***p < 0.05. Scale = 20μm. a Representative image of rhodamine-rhPRG4 treated Prg4−/− macrophages and probed with IC antibody. b Representative
image of rhodamine-rhPRG4 treated Prg4−/− macrophages and probed with anti-CD44 antibody. c Representative image of rhodamine-rhPRG4 treated
Prg4−/− macrophages and probed with anti-TLR2 antibody. d Representative image of rhodamine-rhPRG4 treated Prg4−/− macrophages and probed
with anti-TLR4 antibody. e Colocalization of rhPRG4 and CD44 was higher compared to rhPRG4 and TLR2 colocalization and rhPRG4 and
TLR4 colocalization
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studied their time-dependent MSU crystal phagocytosis
and resultant IL-1β secretion. While we did not observe a
marked difference in the extent of MSU internalization by
macrophages from Prg4 null and competent animals at
4 h, MSU crystals have accumulated in the Prg4−/− macro-
phages compared to the wildtype counterparts by 24 h,
with approximately 3 times the number of intracellular
MSU crystals in Prg4−/− macrophages compared to wild-
type macrophages. The accumulation of urate crystals in-
side Prg4−/− macrophages may be due to enhanced
phagocytosis over time or impaired degradation of intra-
cellular urate crystals in the or a combination of both.
The uptake of MSU by Prg4−/− and wild type macrophages
was reduced by rhPRG4 treatment at 4 h and this effect
was sustained over 24 h. We have also observed an en-
hanced MSU stimulated IL-1β production by Prg4−/− mac-
rophages compared to wild type macrophages with
approximately 3-fold increase in IL-1β production by
knockout macrophages in relation to wild type macro-
phages after incubation for 4 h and remained up to 24 h.
This suggests that Prg4 null macrophages are primed to
the inflammation triggering effect of MSU crystals, which
can be rationalized by the low grade inflammatory pheno-
type of Prg4−/− mice [46]. Our combined findings support
that PRG4 may have an anti-inflammatory biological role
in regulating the activation of tissue macrophages by dan-
ger signals e.g. MSU crystals.
To gain more insight into the molecular target of
rhPRG4 that mediates its anti-phagocytic and
anti-inflammatory effects, we have conducted comparative
efficacy studies of rhPRG4 against antibody-mediated
neutralization of CD44, TLR2 and TLR4 receptors using
MSU challenged Prg4−/− and wildtype macrophages. We
have also performed colocalization studies to identify the
putative receptor target on the surface of macrophages.
Phagocytosis of MSU crystals by human and murine mac-
rophages and downstream IL-1β production were re-
versed by CD44, TLR2 and TLR4 receptor neutralization.
The neutralization of these receptors resulted in a similar
anti-inflammatory efficacy to that of rhPRG4. The inhibi-
tory effect of TLR2 and TLR4 neutralizing antibodies sup-
ports a role for TLR2 and TLR4 in mediating the initial
steps of gout pathogenesis [5]. CD44 is a transmembrane
receptor with an important role in inflammation [47]. In
addition to regulating cellular migration and adhesion,
CD44 receptor has a role in regulating cell signaling path-
ways owing to its ability to regulate signaling protein as-
sembly [47]. Macrophage CD44 receptor was shown to
mediate complement-dependent and independent phago-
cytosis [48, 49]. In addition to its direct phagocytic role,
Fig. 7 Impact of recombinant human proteoglycan-4 (rhPRG4) treatment on differential weight bearing (Right hind limb – Left hind limb; R-L)
and synovial fluid (SF) lavage myeloperoxidase (MPO) activity following intra-articular administration of monosodium urate monohydrate (MSU)
crystals (50μL; 2.5 mg/mL) in the right knee joint of male Lewis rats followed by intra-articular treatments with rhPRG4 (1 mg/mL; 50 μL) or PBS
(50 μL) at 1 h following MSU administration, or no treatment. Differential weight bearing was measured at 3 h (n = 12 in MSU alone and n = 14 in
rhPRG4 or PBS treatments), 6 h (n = 12 in MSU alone and n = 14 in rhPRG4 or PBS treatments) and 24 h (n = 5 in MSU alone and n = 7 in rhPRG4
or PBS treatments) following MSU administration. SF lavage MPO activities were determined at 6 h (n = 7 in each group) and 24 h (n = 5 in each
group) following MSU administration. Data are presented as a scatterplot with the mean value highlighted. *p < 0.001; **p < 0.01; ***p < 0.05. a
rhPRG4 treatment decreased MSU-induced differential weight bearing at 6 h compared to PBS treatment or no treatment. b rhPRG4 treatment
reduced MSU-induced elevation in SF lavage MPO activity at 6 h compared to PBS treatment or no treatment
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CD44 was shown to negatively regulate TLR stimulation
[32, 50, 51]. Neutralization of CD44 using a CD44-specific
antibody was shown to reduce NFκB nuclear translocation
and proinflammatory cytokine expression and production
by macrophages in response to TLR2 ligand stimulation
[32]. The anti-phagocytic activity of CD44 receptor
neutralization, shown in our murine macrophage experi-
ments, provides evidence that CD44 may act as a regula-
tor of MSU induced inflammation in macrophages. The
involvement of CD44 is further highlighted by preferential
colocalization of rhPRG4 with CD44 compared to TLR2
or TLR4 on the surface of macrophages, likely indicating
that the effect of rhPRG4 is based on its CD44 interaction.
The involvement of CD44 in mediating rhPRG4’s effect is
further supported by the higher binding affinity that
rhPRG4 exhibit against CD44 compared to either TLR2
or TLR4 [26, 28, 29]. The involvement of CD44 receptor
in the function of rhPRG4 cannot definitively rule out
other accessory mechanisms. The complexity of the inter-
action between PRG4 and cell surfaces is highlighted by
the unique and multifunctional structure of PRG4. PRG4
was shown to bind to L-selectin in a glycosylation-
dependent manner [52, 53]. Additionally, PRG4 amino
terminal domains are homologous to somatomedin B do-
main of vitronectin and the carboxy terminal contains a
hemopexin domain and may mediate surface binding of
the protein [54].
IL-1β plays a pivotal role in mediating gouty inflam-
mation and IL-1 inhibitors were shown to relieve pain
and inflammation in rodent models and in clinical expe-
riences [55–57]. IL-1 inhibitors do not interfere with
MSU phagocytosis by macrophages and other cells in
the joint and thus do not block the resultant expression
and production of proinflammatory cytokines and che-
mokines. IL-1 inhibitors block the autocrine and para-
crine effects of locally produced IL-1β and hence the
downstream inflammatory cascade. rhPRG4 works at an
earlier point in the gout inflammatory pathway by redu-
cing MSU phagocytosis. The mechanism of action of
rhPRG4 results in an indirect IL-1 antagonist effect, via
reducing IL-1β production and hence attenuating its role
in driving gout pathogenesis. We thus also studied
crystal-induced inflammation in vivo in the rat.
Intra-articular administration of MSU resulted in a spike
in MPO activity at 6 h that gradually resolved by 24 h.
MPO is abundantly expressed and released from neutro-
phils and is a marker of neutrophil tissue infiltration and
oxidative stress [58, 59]. Specific to gout, MPO activity
in articular joint tissues increased and has been previ-
ously correlated with neutrophil influx in a mouse model
of crystal-induced inflammation [21]. rhPRG4 treatment
reduced joint inflammation following MSU challenge.
Hypernociception was evident following MSU challenge
and the time course of mechanical allodynia mirrored
joint inflammation. This is in accordance with previous
reports that demonstrated that synovial tissue COX2
gene expression and associated mechanical allodynia
were significantly increased following MSU administra-
tion in rat knee or ankle joints [60–62]. This novel
in vivo anti-nociceptive and anti-inflammatory efficacy
of rhPRG4 builds upon previously reported efficacy of
rhPRG4 in pre-clinical PTOA models [63–66] and pro-
vides a rationale for further investigation of rhPRG4’s ef-
ficacy as a treatment for acute gout.
Our study was limited by the brief duration of inflam-
mation that was observed in the rat model, which might
have limited our ability to comprehensively characterize
the efficacy of rhPRG4 in vivo. Future study will use a
higher dose of MSU crystals, which has been recently
optimized [67]. Additionally, we have not studied the
inflammatory effect of MSU challenge in Prg4+/+ and
Prg4−/− mice in vivo. In our experiments, we observed a re-
duction in IL-1β gene expression and secreted IL-1β levels
at the 100 μg/ml level following a 6-h incubation period.
Alternatively, we detected an inhibitory effect of rhPRG4
on intracellular mature IL-1β at 200 μg/ml following a 12-h
incubation period. Collectively, these observations demon-
strate the anti-inflammatory potency of rhPRG4.
Conclusion
rhPRG4 inhibited MSU crystal phagocytosis by human and
murine macrophages, reduced NFκB p65 subunit nuclear
translocation and downstream proinflammatory cytokines
and chemokines expression and production in vitro.
Neutralization of CD44, TLR2 and TLR4 receptors on mur-
ine macrophages yielded similar efficacy to rhPRG4, namely
a reduction in MSU phagocytosis and downstream IL-1β
production. rhPRG4 demonstrated a higher binding affinity
and colocalization with the CD44 receptor compared to
TLR2 or TLR4 receptors. These findings suggest that the
CD44 receptor may play a role in regulating MSU phago-
cytosis by macrophages and that rhPRG4’s efficacy is partly
due to its CD44-based mechanism. Intra-articular adminis-
tration of rhPRG4 reduced MPO activity and normalized
weight bearing in a rat model.
Abbreviations
ANOVA: Analysis of Variance; CD44 receptor: Cluster determinant 44 receptor;
Ct: Cycle Threshold; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal
bovine serum; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; HEPES:
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); IκBα: Inhibitor kappa B
alpha; IL-1β: Interleukin-1 beta; IL-8: Interleukin-8; MCP-1: Monocyte chemoattractant
protein-1; MSU: Monosodium urate monohydrate; NFκB: Nuclear Factor Kappa B;
OA: Osteoarthritis; PBS: Phosphate-buffered saline; PRG4: Proteoglycan-4;
qPCR: Quantitative PCR; RA: Rheumatoid arthritis; rhPRG4: Recombinant
human PRG4; RPMI medium: Roswell Park Memorial Institute medium;
S.D.: Standard deviation; TBS-T: Tris-buffered saline Tween 20; TLR2: Toll-like
receptor 2; TLR4: Toll-like receptor 4; TNFα: Tumor Necrosis Factor alpha
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